PLYX
Polaryx Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.04
−4.67%Institutional positioning
13F filings over the trailing two quarters
New 18Increased 3Reduced 2Sold out 5
| Filer | Action | Shares | Filed |
|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 1,658,388 | May 15, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Reduced | 1,657,872 | Aug 13, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Increased | 170,998 | Aug 12, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | New Position | 170,673 | May 15, 2026 |
| MILLENNIUM MANAGEMENT LLC | New Position | 127,525 | May 15, 2026 |
| VANGUARD FIDUCIARY TRUST CO | Increased | 105,072 | Aug 13, 2026 |
| VANGUARD FIDUCIARY TRUST CO | New Position | 104,556 | May 8, 2026 |
| HRT FINANCIAL LP | New Position | 82,094 | Aug 14, 2026 |
| STATE STREET CORP | Unchanged | 58,104 | Aug 7, 2026 |
| STATE STREET CORP | New Position | 58,104 | May 15, 2026 |
| BLACKROCK, INC. | New Position | 41,012 | May 13, 2026 |
| BlackRock, Inc. | Unchanged | 41,012 | Aug 7, 2026 |
| JANE STREET GROUP, LLC | New Position | 31,441 | Aug 14, 2026 |
| NORTHERN TRUST CORP | New Position | 27,987 | May 14, 2026 |
| NORTHERN TRUST CORP | Unchanged | 27,987 | Aug 13, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings